Semin Respir Crit Care Med 2016; 37(03): 358-367
DOI: 10.1055/s-0036-1580693
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

What We Know About the Pathogenesis of Idiopathic Pulmonary Fibrosis

S. Puglisi
1   Department of Clinical and Experimental Medicine, Regional Centre for Interstitial and Rare Lung Diseases, University of Catania, Catania, Italy
,
S. E. Torrisi
1   Department of Clinical and Experimental Medicine, Regional Centre for Interstitial and Rare Lung Diseases, University of Catania, Catania, Italy
,
R. Giuliano
1   Department of Clinical and Experimental Medicine, Regional Centre for Interstitial and Rare Lung Diseases, University of Catania, Catania, Italy
,
V. Vindigni
1   Department of Clinical and Experimental Medicine, Regional Centre for Interstitial and Rare Lung Diseases, University of Catania, Catania, Italy
,
C. Vancheri
1   Department of Clinical and Experimental Medicine, Regional Centre for Interstitial and Rare Lung Diseases, University of Catania, Catania, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
27 May 2016 (online)

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease of unknown cause, occurring in adults, limited to the lungs and associated with the pathologic and radiologic pattern of usual interstitial pneumonia. Prognosis is poor, and most patients die of respiratory failure within 3 to 6 years from the onset of symptoms. Although our understanding of the pathogenesis of IPF has improved over the past two decades, the mechanisms responsible for this disorder have not been clearly defined. Aging is the single most important risk factor, but genetic, environmental, and diverse exogenous factors such as smoking, viral infections, chronic tissue injury (i.e., gastroesophageal reflux disease, traction injury) play contributory roles. In this review, we focus on pathogenetic mechanisms that we think are crucial for the initiation of the fibrotic process and for its progressive evolution. In the early stage of the disease, in the context of the permissive genetic background combined with the presence of specific risk factors, alveolar epithelial cells play a leading role. Subsequent evolution of the fibrotic process and its lethal progression is likely due to the abnormal tissue repair process that takes place in the lung and to the inability to counteract this process. In this phase of the disease, fibroblasts assume a crucial role. Current pharmacological treatment strategies for IPF have only modest value, principally by slowing the course of disease progression. Unfortunately, improvement or cure has not yet been achieved with pharmacological agents. The challenge for the future is to improve the comprehension of the mechanisms involved in the inception and evolution of IPF and their articulated interactions. This is fundamental not only to conceive and develop new drugs against this dreadful disease but also to apply different therapeutic approaches such as drug repositioning and personalized therapies in the management of IPF.

 
  • References

  • 1 Raghu G, Collard HR, Egan JJ , et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183 (6) 788-824
  • 2 Williamson JD, Sadofsky LR, Hart SP. The pathogenesis of bleomycin-induced lung injury in animals and its applicability to human idiopathic pulmonary fibrosis. Exp Lung Res 2015; 41 (2) 57-73
  • 3 Robbe A, Tassin A, Carpentier J , et al. Intratracheal bleomycin aerosolization: the best route of administration for a scalable and homogeneous pulmonary fibrosis rat model?. Biomed Res Int 2015; 2015: 198418
  • 4 Spagnolo P, Rossi G, Cavazza A. Pathogenesis of idiopathic pulmonary fibrosis and its clinical implications. Expert Rev Clin Immunol 2014; 10 (8) 1005-1017
  • 5 Chilosi M, Poletti V, Rossi A. The pathogenesis of COPD and IPF: distinct horns of the same devil?. Respir Res 2012; 13: 3
  • 6 Cottin V. The impact of emphysema in pulmonary fibrosis. Eur Respir Rev 2013; 22 (128) 153-157
  • 7 Lee JS. The role of gastroesophageal reflux and microaspiration in idiopathic pulmonary fibrosis. Clin Pulm Med 2014; 21 (2) 81-85
  • 8 Mitchell PD, Das JP, Murphy DJ , et al. Idiopathic pulmonary fibrosis with emphysema: evidence of synergy among emphysema and idiopathic pulmonary fibrosis in smokers. Respir Care 2015; 60 (2) 259-268
  • 9 Harari S, Caminati A. IPF: new insight on pathogenesis and treatment. Allergy 2010; 65 (5) 537-553
  • 10 Tanjore H, Blackwell TS, Lawson WE. Emerging evidence for endoplasmic reticulum stress in the pathogenesis of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012; 302 (8) L721-L729
  • 11 Macneal K, Schwartz DA. The genetic and environmental causes of pulmonary fibrosis. Proc Am Thorac Soc 2012; 9 (3) 120-125
  • 12 Lee MG, Lee YH. A meta-analysis examining the association between the MUC5B rs35705950 T/G polymorphism and susceptibility to idiopathic pulmonary fibrosis. Inflamm Res 2015; 64 (6) 463-470
  • 13 Huaux F, Lasfargues G, Lauwerys R, Lison D. Lung toxicity of hard metal particles and production of interleukin-1, tumor necrosis factor-α, fibronectin, and cystatin-c by lung phagocytes. Toxicol Appl Pharmacol 1995; 132 (1) 53-62
  • 14 Lison D, Lauwerys R, Demedts M, Nemery B. Experimental research into the pathogenesis of cobalt/hard metal lung disease. Eur Respir J 1996; 9 (5) 1024-1028
  • 15 Zamò A, Poletti V, Reghellin D , et al. HHV-8 and EBV are not commonly found in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22 (2) 123-128
  • 16 Tang YW, Johnson JE, Browning PJ , et al. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol 2003; 41 (6) 2633-2640
  • 17 Lawson WE, Crossno PF, Polosukhin VV , et al. Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. Am J Physiol Lung Cell Mol Physiol 2008; 294 (6) L1119-L1126
  • 18 Lozo Vukovac E, Lozo M, Mise K , et al. Bronchoalveolar pH and inflammatory biomarkers in newly diagnosed IPF and GERD patients: a case-control study. Med Sci Monit 2014; 20: 255-261
  • 19 Savarino E, Carbone R, Marabotto E , et al. Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur Respir J 2013; 42 (5) 1322-1331
  • 20 Appel III JZ, Lee SM, Hartwig MG , et al. Characterization of the innate immune response to chronic aspiration in a novel rodent model. Respir Res 2007; 8: 87
  • 21 Leung J, Cho Y, Lockey RF, Kolliputi N. The role of aging in idiopathic pulmonary fibrosis. Lung 2015; 193 (4) 605-610
  • 22 Rabinovich EI, Kapetanaki MG, Steinfeld I , et al. Global methylation patterns in idiopathic pulmonary fibrosis. PLoS ONE 2012; 7 (4) e33770
  • 23 Sanders YY, Pardo A, Selman M , et al. Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am J Respir Cell Mol Biol 2008; 39 (5) 610-618
  • 24 Huang SK, Fisher AS, Scruggs AM , et al. Hypermethylation of PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts from humans and mice. Am J Pathol 2010; 177 (5) 2245-2255
  • 25 Tzouvelekis A, Kaminski N. Epigenetics in idiopathic pulmonary fibrosis. Biochem Cell Biol 2015; 93 (2) 159-170
  • 26 Yang IV, Schwartz DA. Epigenetics of idiopathic pulmonary fibrosis. Transl Res 2015; 165 (1) 48-60
  • 27 Cisneros J, Hagood J, Checa M , et al. Hypermethylation-mediated silencing of p14(ARF) in fibroblasts from idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012; 303 (4) L295-L303
  • 28 Huang SK, Scruggs AM, McEachin RC, White ES, Peters-Golden M. Lung fibroblasts from patients with idiopathic pulmonary fibrosis exhibit genome-wide differences in DNA methylation compared to fibroblasts from nonfibrotic lung. PLoS ONE 2014; 9 (9) e107055
  • 29 Comer BS, Ba M, Singer CA, Gerthoffer WT. Epigenetic targets for novel therapies of lung diseases. Pharmacol Ther 2015; 147: 91-110
  • 30 Sanders YY, Hagood JS, Liu H, Zhang W, Ambalavanan N, Thannickal VJ. Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice. Eur Respir J 2014; 43 (5) 1448-1458
  • 31 Davies ER, Haitchi HM, Thatcher TH , et al. Spiruchostatin A inhibits proliferation and differentiation of fibroblasts from patients with pulmonary fibrosis. Am J Respir Cell Mol Biol 2012; 46 (5) 687-694
  • 32 Vancheri C, Sortino MA, Tomaselli V , et al. Different expression of TNF-alpha receptors and prostaglandin E(2 )Production in normal and fibrotic lung fibroblasts: potential implications for the evolution of the inflammatory process. Am J Respir Cell Mol Biol 2000; 22 (5) 628-634
  • 33 Coward WR, Feghali-Bostwick CA, Jenkins G, Knox AJ, Pang L. A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis. FASEB J 2014; 28 (7) 3183-3196
  • 34 Huang SK, Scruggs AM, Donaghy J , et al. Histone modifications are responsible for decreased Fas expression and apoptosis resistance in fibrotic lung fibroblasts. Cell Death Dis 2013; 4: e621
  • 35 Vancheri C. Common pathways in idiopathic pulmonary fibrosis and cancer. Eur Respir Rev 2013; 22 (129) 265-272
  • 36 Yang S, Banerjee S, de Freitas A , et al. Participation of miR-200 in pulmonary fibrosis. Am J Pathol 2012; 180 (2) 484-493
  • 37 Cushing L, Kuang PP, Qian J , et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol 2011; 45 (2) 287-294
  • 38 Pandit KV, Corcoran D, Yousef H , et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010; 182 (2) 220-229
  • 39 Yamada M, Kubo H, Ota C , et al. The increase of microRNA-21 during lung fibrosis and its contribution to epithelial-mesenchymal transition in pulmonary epithelial cells. Respir Res 2013; 14: 95
  • 40 Pottier N, Maurin T, Chevalier B , et al. Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: implication in epithelial-mesenchymal interactions. PLoS ONE 2009; 4 (8) e6718
  • 41 Oak SR, Murray L, Herath A , et al. A micro RNA processing defect in rapidly progressing idiopathic pulmonary fibrosis. PLoS ONE 2011; 6 (6) e21253
  • 42 Nogee LM, Dunbar III AE, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001; 344 (8) 573-579
  • 43 Beers MF, Mulugeta S. Surfactant protein C biosynthesis and its emerging role in conformational lung disease. Annu Rev Physiol 2005; 67: 663-696
  • 44 Willander H, Hermansson E, Johansson J, Presto J. BRICHOS domain associated with lung fibrosis, dementia and cancer—a chaperone that prevents amyloid fibril formation?. FEBS J 2011; 278 (20) 3893-3904
  • 45 Mulugeta S, Nguyen V, Russo SJ, Muniswamy M, Beers MF. A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation. Am J Respir Cell Mol Biol 2005; 32 (6) 521-530
  • 46 Maitra M, Wang Y, Gerard RD, Mendelson CR, Garcia CK. Surfactant protein A2 mutations associated with pulmonary fibrosis lead to protein instability and endoplasmic reticulum stress. J Biol Chem 2010; 285 (29) 22103-22113
  • 47 Wang Y, Kuan PJ, Xing C , et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet 2009; 84 (1) 52-59
  • 48 Hojo S, Fujita J, Yamadori I , et al. Heterogeneous point mutations of the p53 gene in pulmonary fibrosis. Eur Respir J 1998; 12 (6) 1404-1408
  • 49 Uematsu K, Yoshimura A, Gemma A , et al. Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis. Cancer Res 2001; 61 (23) 8527-8533
  • 50 Demopoulos K, Arvanitis DA, Vassilakis DA, Siafakas NM, Spandidos DA. MYCL1, FHIT, SPARC, p16(INK4) and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis. J Cell Mol Med 2002; 6 (2) 215-222
  • 51 Antoniou KM, Samara KD, Lasithiotaki I , et al. Differential telomerase expression in idiopathic pulmonary fibrosis and non-small cell lung cancer. Oncol Rep 2013; 30 (6) 2617-2624
  • 52 Calado RT, Young NS. Telomere diseases. N Engl J Med 2009; 361 (24) 2353-2365
  • 53 Seibold MA, Wise AL, Speer MC , et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364 (16) 1503-1512
  • 54 Zhang Y, Noth I, Garcia JG, Kaminski N. A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N Engl J Med 2011; 364 (16) 1576-1577
  • 55 Peljto AL, Steele MP, Fingerlin TE , et al. The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. Chest 2012; 142 (6) 1584-1588
  • 56 Copley SJ, Wells AU, Hawtin KE , et al. Lung morphology in the elderly: comparative CT study of subjects over 75 years old versus those under 55 years old. Radiology 2009; 251 (2) 566-573
  • 57 López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013; 153 (6) 1194-1217
  • 58 Moskalev AA, Shaposhnikov MV, Plyusnina EN , et al. The role of DNA damage and repair in aging through the prism of Koch-like criteria. Ageing Res Rev 2013; 12 (2) 661-684
  • 59 Korfei M, Schmitt S, Ruppert C , et al. Comparative proteomic analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and lung transplant donor lungs. J Proteome Res 2011; 10 (5) 2185-2205
  • 60 Chilosi M, Poletti V, Murer B , et al. Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of deltaN-p63. Lab Invest 2002; 82 (10) 1335-1345
  • 61 Chilosi M, Doglioni C. Constitutive p63 expression in airway basal cells. A molecular target in diffuse lung diseases. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18 (1) 23-26
  • 62 Lawson WE, Loyd JE, Degryse AL. Genetics in pulmonary fibrosis—familial cases provide clues to the pathogenesis of idiopathic pulmonary fibrosis. Am J Med Sci 2011; 341 (6) 439-443
  • 63 Armanios MY, Chen JJ, Cogan JD , et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007; 356 (13) 1317-1326
  • 64 Tsakiri KD, Cronkhite JT, Kuan PJ , et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A 2007; 104 (18) 7552-7557
  • 65 Cronkhite JT, Xing C, Raghu G , et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178 (7) 729-737
  • 66 Chilosi M, Carloni A, Rossi A, Poletti V. Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema. Transl Res 2013; 162 (3) 156-173
  • 67 Trovato-Salinaro A, Trovato-Salinaro E, Failla M , et al. Altered intercellular communication in lung fibroblast cultures from patients with idiopathic pulmonary fibrosis. Respir Res 2006; 7: 122
  • 68 Mori R, Power KT, Wang CM, Martin P, Becker DL. Acute downregulation of connexin43 at wound sites leads to a reduced inflammatory response, enhanced keratinocyte proliferation and wound fibroblast migration. J Cell Sci 2006; 119 (Pt 24) 5193-5203
  • 69 Chuquimia OD, Petursdottir DH, Periolo N, Fernández C. Alveolar epithelial cells are critical in protection of the respiratory tract by secretion of factors able to modulate the activity of pulmonary macrophages and directly control bacterial growth. Infect Immun 2013; 81 (1) 381-389
  • 70 Ward HE, Nicholas TE. Alveolar type I and type II cells. Aust N Z J Med 1984; 14 (5) (Suppl. 03) 731-734
  • 71 Korfei M, Ruppert C, Mahavadi P , et al. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178 (8) 838-846
  • 72 Li X, Shu R, Filippatos G, Uhal BD. Apoptosis in lung injury and remodeling. J Appl Physiol (1985) 2004; 97 (4) 1535-1542
  • 73 Sisson TH, Mendez M, Choi K , et al. Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med 2010; 181 (3) 254-263
  • 74 Uhal BD. The role of apoptosis in pulmonary fibrosis. Eur Respir Rev 2008; 17: 138-144
  • 75 Schröder M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem 2005; 74: 739-789
  • 76 van Rijt SH, Keller IE, John G , et al. Acute cigarette smoke exposure impairs proteasome function in the lung. Am J Physiol Lung Cell Mol Physiol 2012; 303 (9) L814-L823
  • 77 Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997; 155 (1) 242-248
  • 78 Jorgensen E, Stinson A, Shan L, Yang J, Gietl D, Albino AP. Cigarette smoke induces endoplasmic reticulum stress and the unfolded protein response in normal and malignant human lung cells. BMC Cancer 2008; 8: 229
  • 79 Bueno M, Lai YC, Romero Y , et al. PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis. J Clin Invest 2015; 125 (2) 521-538
  • 80 Kim J, Byun JW, Choi I , et al. PINK1 deficiency enhances inflammatory cytokine release from acutely prepared brain slices. Exp Neurobiol 2013; 22 (1) 38-44
  • 81 Zhang Q, Raoof M, Chen Y , et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464 (7285) 104-107
  • 82 Oka T, Hikoso S, Yamaguchi O , et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 2012; 485 (7397) 251-255
  • 83 Ichimura Y, Waguri S, Sou YS , et al. Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol Cell 2013; 51 (5) 618-631
  • 84 Vestergaard PF, Hansen M, Frystyk J , et al. Serum levels of bioactive IGF1 and physiological markers of ageing in healthy adults. Eur J Endocrinol 2014; 170 (2) 229-236
  • 85 Honeyman L, Bazett M, Tomko TG, Haston CK. MicroRNA profiling implicates the insulin-like growth factor pathway in bleomycin-induced pulmonary fibrosis in mice. Fibrogenesis Tissue Repair 2013; 6 (1) 16
  • 86 Tanjore H, Cheng DS, Degryse AL , et al. Alveolar epithelial cells undergo epithelial-to-mesenchymal transition in response to endoplasmic reticulum stress. J Biol Chem 2011; 286 (35) 30972-30980
  • 87 Zhong Q, Zhou B, Ann DK , et al. Role of endoplasmic reticulum stress in epithelial-mesenchymal transition of alveolar epithelial cells: effects of misfolded surfactant protein. Am J Respir Cell Mol Biol 2011; 45 (3) 498-509
  • 88 Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 2007; 293 (3) L525-L534
  • 89 Jonsdottir HR, Arason AJ, Palsson R , et al. Basal cells of the human airways acquire mesenchymal traits in idiopathic pulmonary fibrosis and in culture. Lab Invest 2015; 95 (12) 1418-1428
  • 90 Kage H, Borok Z. EMT and interstitial lung disease: a mysterious relationship. Curr Opin Pulm Med 2012; 18 (5) 517-523
  • 91 Hinz B, Phan SH, Thannickal VJ , et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol 2012; 180 (4) 1340-1355
  • 92 Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol 2007; 127 (3) 526-537
  • 93 McAnulty RJ. Fibroblasts and myofibroblasts: their source, function and role in disease. Int J Biochem Cell Biol 2007; 39 (4) 666-671
  • 94 Darby IA, Hewitson TD. Fibroblast differentiation in wound healing and fibrosis. Int Rev Cytol 2007; 257: 143-179
  • 95 Moodley YP, Misso NL, Scaffidi AK , et al. Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs. Am J Respir Cell Mol Biol 2003; 29 (4) 490-498
  • 96 Houchen CW, Sturmoski MA, Anant S, Breyer RM, Stenson WF. Prosurvival and antiapoptotic effects of PGE2 in radiation injury are mediated by EP2 receptor in intestine. Am J Physiol Gastrointest Liver Physiol 2003; 284 (3) G490-G498
  • 97 Jovanovic DV, Mineau F, Notoya K, Reboul P, Martel-Pelletier J, Pelletier JP. Nitric oxide induced cell death in human osteoarthritic synoviocytes is mediated by tyrosine kinase activation and hydrogen peroxide and/or superoxide formation. J Rheumatol 2002; 29 (10) 2165-2175
  • 98 Kim H, Rhee SH, Pothoulakis C, Lamont JT. Inflammation and apoptosis in Clostridium difficile enteritis is mediated by PGE2 up-regulation of Fas ligand. Gastroenterology 2007; 133 (3) 875-886
  • 99 Chang W, Wei K, Jacobs SS, Upadhyay D, Weill D, Rosen GD. SPARC suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of beta-catenin. J Biol Chem 2010; 285 (11) 8196-8206
  • 100 Sisson TH, Maher TM, Ajayi IO , et al. Increased survivin expression contributes to apoptosis-resistance in IPF fibroblasts. Adv Biosci Biotechnol 2012; 3 (6A): 657-664
  • 101 Bagnato G, Harari S. Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev 2015; 24 (135) 102-114